Prediction of preeclampsia/eclampsia in pregnant women

A prospective, randomised INterventional Study evaluating the short-term PredIction of pReeclampsia/Eclampsia in pregnant women with suspected preeclampsia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN87470468

Enrollment

366

Registered

2015-11-20

Start date

2015-06-11

Completion date

Unknown

Last updated

2022-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Reproductive Health & Childbirth

Interventions

Patients attending the Maternity Assessment Unit, Day Assessment Unit, Antenatal Clinics and Delivery Suite/Labour Ward with suspected preeclampsia will be approached. Consenting participants who meet

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Female aged between 18-45 years 2. Pregnant >24 weeks 3. Able to consent 4. Singleton pregnancy 5. New onset hypertension (Stratified as below – Management) AND/OR 6. New onset proteinuria AND/OR 7. New onset oedema/headache/visual Disturbance AND/OR 8. New onset hepatic/liver tenderness AND/OR epigastric pain AND/OR 9. Any other clinical suspicion of PE

Exclusion criteria

Exclusion criteria: 1. Unable to consent 2. Age less than 18 or over 45 at the time of recruitment 3. Unable to speak English well enough to understand the study information 4. Unwilling to participate 5. Preexisting preeclampsia 6. Multiple pregnancy or higher order pregnancy 7. Any significant disease or disorder which in the opinion of the investigator may either put the participants at risk or may influence the result of the study or the participant’s ability to participate in the study

Design outcomes

Primary

Measure	Time frame
Inpatient admission rate measured using electronic patient records (EPR) and case-note review at baseline, 1 week and time of delivery.	—

Secondary

Measure	Time frame
1. Incidence of preeclampsia is measured according to NICE guidelines at baseline, 1 week and time of delivery 2. Re-admission rate is measured using EPR at recruitment at baseline, 1 week and time of delivery 3. Birth weight is measured using EPR and casenotes at time of delivery 4. SCBU admission rate is measured using EPR at time of delivery 5. Foetal growth is measured using antenatal ultrasound scanning at baseline, 1 week and time of delivery 6. Total blood count and platelet count is measured using blood testing at baseline, 1 week and time of delivery 7. Renal and hepatic function is measured using blood testing at baseline, 1 week and time of delivery	—

Measure

Time frame

1. Incidence of preeclampsia is measured according to NICE guidelines at baseline, 1 week and time of delivery 2. Re-admission rate is measured using EPR at recruitment at baseline, 1 week and time of delivery 3. Birth weight is measured using EPR and casenotes at time of delivery 4. SCBU admission rate is measured using EPR at time of delivery 5. Foetal growth is measured using antenatal ultrasound scanning at baseline, 1 week and time of delivery 6. Total blood count and platelet count is measured using blood testing at baseline, 1 week and time of delivery 7. Renal and hepatic function is measured using blood testing at baseline, 1 week and time of delivery

—

Countries

England, United Kingdom

Contacts

Public ContactGeorgina Longley

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 20, 2026